

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): August 3, 2015**

---

**INTEGRA LIFESCIENCES HOLDINGS CORPORATION**  
(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-26224**  
(Commission  
File Number)

**51-0317849**  
(I.R.S. Employer  
Identification No.)

**311 Enterprise Drive**  
**Plainsboro, NJ 08536**  
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code: (609) 275-0500**

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 8.01 Other Events**

On August 3, 2015, Integra LifeSciences Holdings Corporation (the “Company”) announced the commencement of an underwritten public offering of \$200,000,000 of shares of its common stock. The Company expects to grant the underwriters of the offering an option to purchase up to \$30,000,000 of additional shares of its common stock. A copy of the press release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS****(d) Exhibits**

99.1 Press Release, dated August 3, 2015, issued by Integra LifeSciences Holdings Corporation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: August 3, 2015

By: /s/ Glenn G. Coleman

Glenn G. Coleman

Title: Corporate Vice President and Chief Financial Officer

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated August 3, 2015, issued by Integra LifeSciences Holdings Corporation.



August 3, 2015

### **Integra LifeSciences Announces Proposed Public Offering of Common Stock**

PLAINSBORO, N.J., Aug. 3, 2015 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it intends to offer, subject to market conditions and other factors, \$200,000,000 of its common stock in an underwritten public offering registered under the Securities Act of 1933, as amended. In connection with the offering, Integra expects to grant the underwriters a 30-day option to purchase an additional \$30,000,000 of its common stock.

Integra intends to use the net proceeds from the offering, including any net proceeds received from an exercise of the underwriters' option to purchase additional shares, to reduce outstanding borrowings under Integra's senior credit facility.

The shares will be issued pursuant to an effective shelf registration statement on Form S-3. Before investing in the offering, interested parties should read the prospectus for such offering and the other documents Integra has filed with the Securities and Exchange Commission.

J.P. Morgan, Wells Fargo Securities and RBC Capital Markets are acting as joint book-running managers for the offering. The offering is being made by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling (866) 803-9204, from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, by calling (800) 326-5897 or by emailing [cmclientsupport@wellsfargo.com](mailto:cmclientsupport@wellsfargo.com), or from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Phone: 877-822-4089; Email: [equityprospectus@rbccm.com](mailto:equityprospectus@rbccm.com). Electronic copies of the prospectus and related prospectus supplement may be obtained by visiting EDGAR on the SEC's website at <http://www.sec.gov>.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction. Any offer, if at all, will be made only by means of a prospectus and related prospectus supplement forming a part of the effective shelf registration statement.

### **About Integra**

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit [www.integralife.com](http://www.integralife.com).

---

## Forward-Looking Statements

Certain statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include Integra's intention to conduct the offering and its intended use of proceeds from the offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions about Integra's business. Integra's actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those set forth under the heading "Risk Factors" in Integra's filings with the Securities and Exchange Commission, including Integra's Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Integra undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You can identify these forward-looking statements by forward-looking words such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" and similar expressions in this press release.

CONTACT: Michael Beaulieu  
(609) 750-2827  
[michael.beaulieu@integralife.com](mailto:michael.beaulieu@integralife.com)

Investor Relations:  
Angela Steinway  
(609) 936-2268  
[angela.steinway@integralife.com](mailto:angela.steinway@integralife.com)